DE69831971T2 - Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer - Google Patents

Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer Download PDF

Info

Publication number
DE69831971T2
DE69831971T2 DE69831971T DE69831971T DE69831971T2 DE 69831971 T2 DE69831971 T2 DE 69831971T2 DE 69831971 T DE69831971 T DE 69831971T DE 69831971 T DE69831971 T DE 69831971T DE 69831971 T2 DE69831971 T2 DE 69831971T2
Authority
DE
Germany
Prior art keywords
amyloid
peptide
disease
alzheimer
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69831971T
Other languages
German (de)
English (en)
Other versions
DE69831971D1 (de
Inventor
L. Howard WEINER
J. Dennis SELKOE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Neuralab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26747618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69831971(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralab Ltd filed Critical Neuralab Ltd
Publication of DE69831971D1 publication Critical patent/DE69831971D1/de
Application granted granted Critical
Publication of DE69831971T2 publication Critical patent/DE69831971T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Engine Equipment That Uses Special Cycles (AREA)
  • Steroid Compounds (AREA)
DE69831971T 1997-12-03 1998-12-03 Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer Expired - Lifetime DE69831971T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6721997P 1997-12-03 1997-12-03
US67219P 1997-12-03
US7969798P 1998-03-27 1998-03-27
US79697P 1998-03-27
PCT/US1998/025694 WO1999027949A1 (en) 1997-12-03 1998-12-03 METHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASE

Publications (2)

Publication Number Publication Date
DE69831971D1 DE69831971D1 (de) 2006-03-02
DE69831971T2 true DE69831971T2 (de) 2006-07-06

Family

ID=26747618

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1033998T Pending DE1033998T1 (de) 1997-12-03 1998-12-03 Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer
DE69831971T Expired - Lifetime DE69831971T2 (de) 1997-12-03 1998-12-03 Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1033998T Pending DE1033998T1 (de) 1997-12-03 1998-12-03 Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer

Country Status (8)

Country Link
EP (1) EP1033998B1 (enExample)
JP (2) JP2002511385A (enExample)
AT (1) ATE306931T1 (enExample)
AU (1) AU742970C (enExample)
CA (1) CA2312475C (enExample)
DE (2) DE1033998T1 (enExample)
ES (1) ES2253839T3 (enExample)
WO (1) WO1999027949A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
CA2312475C (en) * 1997-12-03 2010-08-03 Brigham And Women's Hospital Method of suppressing .beta.-amyloid-related changes in alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU7487301A (en) 2000-05-22 2001-12-03 Univ New York Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
CA2466841A1 (en) 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003250110C1 (en) 2002-07-19 2008-05-29 Novartis Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
PL2004688T5 (pl) 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US8906382B2 (en) 2011-07-19 2014-12-09 New York University Method for treating amyloid disease
EP2916831A4 (en) * 2012-11-09 2016-07-13 3E Therapeutics Corp RADIOGRAPHIC CONTRAST MEDIUM COMPOSITIONS AND METHODS OF USE FOR TREATING INFLAMMATION AND CONDITIONS ASSOCIATED WITH INFLAMMATION.
JO3537B1 (ar) 2014-07-10 2020-07-05 Bioarctic Neuroscience Ab أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
CA2081482C (en) * 1990-04-27 2000-11-21 Ellis L. Kline Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization
DE69521700T2 (de) * 1994-05-25 2001-10-25 John Mcmichael Mittel und methoden zur behandlung von plaque-krankheiten
AU6113896A (en) * 1995-06-05 1996-12-24 Brigham And Women's Hospital Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production
WO1997018855A1 (en) * 1995-11-21 1997-05-29 Eduard Naumovich Lerner Device for enhanced delivery of biologically active substances and compounds in an organism
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
JPH09208485A (ja) * 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
CA2312475C (en) * 1997-12-03 2010-08-03 Brigham And Women's Hospital Method of suppressing .beta.-amyloid-related changes in alzheimer's disease

Also Published As

Publication number Publication date
ATE306931T1 (de) 2005-11-15
DE1033998T1 (de) 2001-05-23
WO1999027949A1 (en) 1999-06-10
AU742970B2 (en) 2002-01-17
EP1033998A1 (en) 2000-09-13
EP1033998A4 (en) 2003-06-04
CA2312475A1 (en) 1999-06-10
DE69831971D1 (de) 2006-03-02
EP1033998B1 (en) 2005-10-19
CA2312475C (en) 2010-08-03
ES2253839T3 (es) 2006-06-01
JP2002511385A (ja) 2002-04-16
AU1709999A (en) 1999-06-16
JP2010215627A (ja) 2010-09-30
WO1999027949A9 (en) 1999-09-10
AU742970C (en) 2003-03-20

Similar Documents

Publication Publication Date Title
DE69831971T2 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DE69332518T2 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
DE69127470T2 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
DE69132688T2 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69033487T2 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
DE69837324T2 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
DE69126304T2 (de) Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
DE69526728T3 (de) Verwendung von IL-12 und IL-12 Antagonisten zur Herstellung eines Arzneimittels für Behandlung von Autoimmunkrankheiten
DE69133516T2 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DE69521700T2 (de) Mittel und methoden zur behandlung von plaque-krankheiten
Diem et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis
DE69830582T2 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
DE3519361A1 (de) (gamma)-ifn als wirkstoff zur hemmung (verhinderung) von abbauprozessen im knochen
JP2019518034A (ja) 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
DE69902127T2 (de) Histon beinhaltende zusammenstellung zur behandlung von rheumatischer arthritis
EP1521588A2 (de) Verwendung von inhibitoren der alanyl-aminopeptidasen und diese umfassende pharmazeutischen zubereitungen
DE3530767C2 (enExample)
DE69533311T2 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE69630527T2 (de) Vorbeugung einer krankheit mit diabetes charakter
DE69813070T2 (de) Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex
DE69528168T2 (de) Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes
DE60129552T2 (de) E-selectin zur behandlung oder vorbeugung von schlaganfall
DE4413938A1 (de) Peptide als Therapeutikum für Autoimmunerkrankungen
EP1216047B1 (de) Kombination von loteprednol und beta2-adrenozeptor-agonisten und ihre verwendung durch inhalation zur behandlung von asthma bronchiale
AU781126B2 (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: ELAN PHARMA INTERNATIONAL LTD., ATHLONE, WESTM, IE

8365 Fully valid after opposition proceedings